HEMATOLOGIC NEOPLASM WITH GERMLINE GATA2 MUTATION

Clinical trials for HEMATOLOGIC NEOPLASM WITH GERMLINE GATA2 MUTATION explained in plain language.

Never miss a new study

Get alerted when new HEMATOLOGIC NEOPLASM WITH GERMLINE GATA2 MUTATION trials appear

Sign up with your email to follow new studies for HEMATOLOGIC NEOPLASM WITH GERMLINE GATA2 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New transplant method aims to tame dangerous side effects for rare blood disease patients

Disease control Completed

This study tested a new combination of drugs given before a bone marrow or blood stem cell transplant. The goal was to see if this new 'conditioning' regimen could help patients with rare bone marrow failure diseases have fewer and less severe complications after their transplant…

Matched conditions: HEMATOLOGIC NEOPLASM WITH GERMLINE GATA2 MUTATION

Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

HEMATOLOGIC NEOPLASM WITH GERMLINE GATA2 MUTATION

Get alerted when new HEMATOLOGIC NEOPLASM WITH GERMLINE GATA2 MUTATION trials appear

New transplant method aims to tame dangerous side effects for rare blood disease patients